Investigational Drug Information for Capivasertib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Capivasertib?
Capivasertib is an investigational drug.
There have been 23 clinical trials for Capivasertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 16th 2020.
The most common disease conditions in clinical trials are Breast Neoplasms, Prostatic Neoplasms, and Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Parexel.
There are one hundred and thirty-four US patents protecting this investigational drug and one international patent.
Summary for Capivasertib
| US Patents | 134 |
| International Patents | 1,371 |
| US Patent Applications | 483 |
| WIPO Patent Applications | 418 |
| Japanese Patent Applications | 169 |
| Clinical Trial Progress | Phase 1 (2020-04-16) |
| Vendors | 56 |
Recent Clinical Trials for Capivasertib
| Title | Sponsor | Phase |
|---|---|---|
| Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC | National Taiwan University Hospital | Phase 2 |
| A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss | VA Office of Research and Development | Phase 2 |
| A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib) | Quotient Sciences | Phase 1 |
Clinical Trial Summary for Capivasertib
Top disease conditions for Capivasertib
Top clinical trial sponsors for Capivasertib
US Patents for Capivasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Capivasertib | See Plans and Pricing | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | See Plans and Pricing |
| Capivasertib | See Plans and Pricing | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) | See Plans and Pricing |
| Capivasertib | See Plans and Pricing | Polymeric nanoparticles and methods of making and using same | Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY) | See Plans and Pricing |
| Capivasertib | See Plans and Pricing | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide | AstraZeneca AB (Sodertalje, SE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Capivasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Capivasertib | Australia | AU2015244171 | 2034-04-11 | See Plans and Pricing |
| Capivasertib | Australia | AU2015244179 | 2034-04-11 | See Plans and Pricing |
| Capivasertib | Canada | CA2945128 | 2034-04-11 | See Plans and Pricing |
| Capivasertib | Canada | CA2945129 | 2034-04-11 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
